RxDoctor Payments Data

Alan Yamada, MD

Urology · Arcadia, CANPI 1760456040

Payments from drug & device makers

$12,864in general payments, 2019–2025

Across 422 payments — averaging $30.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Astellas Pharma US Inc$1K
  • Neotract Inc.$1K
  • AbbVie$947
  • Myriad Genetic Laboratories, Inc.$862
  • Procept Biorobotics Corporation$796
  • plus $6K from 37 others

What the payments were for

  • Travel & lodging$1,81514%
  • Food & beverage$10,59282%
  • Education$4574%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,864 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$805,614
Medicare patients
1,153
Services billed
9,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron321$218,472
MyrbetriqMirabegron214$149,995
BotoxOnabotulinumtoxina54$49,466
OrgovyxRelugolix13$35,327
Tamsulosin Hcl1,324$16,705
PremarinEstrogens, Conjugated37$15,868
Finasteride998$12,828
Solifenacin Succinate95$11,040
Potassium Citrate ErPotassium Citrate56$6,521
Estradiol98$6,117
Silodosin71$5,219
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim603$5,155
Trimethoprim69$5,136
Dutasteride120$4,675
Testosterone37$4,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$655$253,798334 claims
Astellas Pharma US IncMyrbetriq$1,208$149,995214 claims
AbbVieBotox$947$49,46654 claims
PfizerPremarin$590$15,86837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,324 urology providers in California.

Other urology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →